Relmada Therapeutics (RLMD) Notes Payables (2014 - 2019)
Relmada Therapeutics (RLMD) reported Notes Payables of $110247.0 for Q4 2019, down 3.88% year-over-year from $114700.0 in Q4 2018, and down 56.92% quarter-over-quarter from $255925.0 in Q3 2019.
Relmada Therapeutics (RLMD) Notes Payables (2014 - 2019) Analysis & Trends
Relmada Therapeutics (RLMD) has 6 years of Notes Payables data on file, last reported at $110247.0 in Q4 2019.
- Notes Payables for Q4 2019 came in at $110247.0, down 3.88% year-over-year; the trailing twelve-month figure through Dec 2019 was $110247.0 (down 3.88% YoY), and the FY2019 annual result was $110247.0, changed N/A from the prior year.
- Notes Payables fell to $110247.0 in Q4 2019 per RLMD's latest filing, from $255925.0 in the prior quarter.
- Over five years, Notes Payables peaked at $364204.0 in Q2 2019 and troughed at $27583.0 in Q1 2017.
- A 5-year average of $170744.5 and a median of $170418.0 in 2015 frame the typical range for Notes Payables.
- The sharpest annual moves came in 2015 and 2016: Notes Payables surged 352.05% in 2015, then fell 6.78% in 2016.
- A 5-year view of Notes Payables shows it stood at $88533.0 in 2015, then climbed by 24.25% to $110000.0 in 2016, then rose by 0.93% to $111020.0 in 2017, then gained by 3.31% to $114700.0 in 2018, then retreated by 3.88% to $110247.0 in 2019.
- Business Quant data shows RLMD's Notes Payables at $110247.0 in Q4 2019, $255925.0 in Q3 2019, and $364204.0 in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Relmada Therapeutics | 581.07 Mn | 581.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 110,247.00 |
| Sep 30, 2019 | 255,925.00 |
| Jun 30, 2019 | 364,204.00 |
| Mar 31, 2019 | 28,769.00 |
| Dec 31, 2018 | 114,700.00 |
| Sep 30, 2018 | 200,200.00 |
| Jun 30, 2018 | 285,170.00 |
| Mar 31, 2018 | 27,880.00 |
| Dec 31, 2017 | 111,020.00 |
| Sep 30, 2017 | 194,164.00 |
| Jun 30, 2017 | 276,700.00 |
| Mar 31, 2017 | 27,583.00 |
| Dec 31, 2016 | 110,000.00 |
| Sep 30, 2016 | 164,436.00 |
| Jun 30, 2016 | 273,670.00 |
| Dec 31, 2015 | 88,533.00 |
| Sep 30, 2015 | 176,400.00 |
| Jun 30, 2015 | 263,800.00 |
| Dec 31, 2014 | 38,088.00 |
| Sep 30, 2014 | 148,321.00 |